CPK or strength?

Description

In idiopathic inflammatory myopathies (IIM), “remission” is not a single universally accepted state.

Across studies and working definitions, remission usually means no clinically active myositis (and no active extramuscular disease), and many—but not all—definitions also require normalization of muscle enzymes (including CK).

Explanation

1) CK is a biomarker of muscle injury/necrosis, not a direct readout of strength

Serum CK broadly reflects the extent of muscle necrosis/injury, which is why it can be normal despite active inflammatory myopathy (e.g., less necrotizing phenotypes, low muscle mass, chronic atrophy), and why it can be elevated for reasons unrelated to active immune myositis (exercise, drugs, endocrine disease, macro-CK, etc.).

2) “Improvement” criteria (trials) ≠ “Remission” criteria (inactive disease)

The 2016 ACR/EULAR myositis response framework (TIS) is a composite improvement metric using IMACS core set measures, where muscle enzymes are only one component; it does not require CK normalization to declare improvement.

Clinically, the same principle holds: a patient is not “in remission” just because CK fell, and they’re not necessarily “not in remission” just because CK is still high—you must anchor the decision in objective strength/function and global disease activity.

3) When remission is defined strictly, CK normalization is typically part of it

A clear example (often cited because it is explicit) is the IMACS-derived pediatric definition used in juvenile DM cohorts: complete clinical response required normal strength and normal muscle enzyme levels sustained for ≥6 months (on therapy), and clinical remission required the same off therapy.

In adults, a 2025 narrative review by the Myositis Clinical Trials Consortium emphasizes that published adult remission definitions vary, but commonly combine: physician assessment, muscle strength, laboratory normalization, and medication tapering/discontinuation—often with a ≥6-month duration requirement.

Result

What you can say in practice (evidence-aligned, defensible)

• If you mean “strict remission / inactive myositis”: the most defensible position is clinical quiescence plus (near-)normalization of CK (and other muscle enzymes) sustained over time, because many remission definitions explicitly incorporate lab normalization.
• If you mean “clinical remission / functional remission” at the bedside: the patient should be objectively strong with stable/improving function and low global disease activity, and CK is interpreted as a supporting signal—not the deciding one. Response assessment should not be based on CK alone.

How to handle the common dilemma: “strong patient, CK still elevated”

1. First assume CK is “actionable,” then try to disprove it. Re-check CK after rest, review exertion, meds (statins), thyroid, macro-CK, renal issues; trend other enzymes. Persistent CK elevation without clear myopathy is common and requires careful assessment rather than reflex escalation.
2. Look for discordance signals (new weakness, endurance decline, dysphagia, rising MRI edema, active EMG, worsening extramuscular disease). If present, treat as ongoing activity regardless of “strength looks good.”
3. If no objective activity is found and strength/function are stable, it is reasonable to document clinical remission with biochemical hyperCKemia of unclear/alternate etiology, and avoid immunosuppression-by-lab alone—while continuing surveillance.